Ultragenyx Pharmaceutical - RARE Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $111.58
Forecasted Upside: 170.37 %
Number of Analysts: 8
Breakdown:
0 Sell Ratings
1 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$41.27 As of 09/28/2022 01:00 AM ET

▲ +0.98 (2.43%)

1 month | 3 months | 12 months

Get New Ultragenyx Pharmaceutical Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for RARE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RARE

^$111.58

▲ +170.37% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $111.58, with a high forecast of $142.00 and a low forecast of $60.00. The average price target represents a 170.37% upside from the last price of $41.27.

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Ultragenyx Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/6/2021

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/5/2021

0 strong buy ratings
12 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

10/3/2021

0 strong buy ratings
12 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

1/1/2022

0 strong buy ratings
9 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

4/1/2022

0 strong buy ratings
7 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

6/30/2022

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/29/2022

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/28/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/9/2022	Evercore ISI	Lower Target		$60.00	Low
8/3/2022	Citigroup	Lower Target		$146.00 ➝ $142.00	Low
7/29/2022	Barclays	Lower Target		$141.00 ➝ $105.00	Low
7/28/2022	Piper Sandler	Lower Target	Overweight	$135.00 ➝ $130.00	Low
7/1/2022	Stifel Nicolaus	Lower Target	Buy	$176.00 ➝ $142.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Neutral	$139.00 ➝ $101.00	Low
5/18/2022	Piper Sandler	Lower Target	Overweight	$170.00 ➝ $135.00	Medium
5/6/2022	Cowen	Lower Target		$124.00 ➝ $99.00	High
5/6/2022	Cowen	Lower Target		$124.00 ➝ $99.00	High
3/16/2022	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$99.00 ➝ $105.00	High
2/11/2022	Morgan Stanley	Lower Target	Overweight	$120.00 ➝ $118.00	High
2/11/2022	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$132.00	Low
2/1/2022	Morgan Stanley	Lower Target	Overweight	$156.00 ➝ $120.00	High
10/5/2021	SVB Leerink	Reiterated Rating	Buy		Medium
9/30/2021	HC Wainwright	Initiated Coverage	Buy	$106.00	High
8/19/2021	UBS Group	Initiated Coverage	Sell	$73.00	Medium
8/3/2021	Wedbush	Lower Target	Neutral	$106.00 ➝ $91.00	High
8/3/2021	Barclays	Lower Target	Overweight	$178.00 ➝ $141.00	High
7/15/2021	Guggenheim	Initiated Coverage	Neutral	$84.74	Low
6/29/2021	Bank of America	Upgrade	Neutral ➝ Buy	$162.00	High
5/9/2021	SVB Leerink	Initiated Coverage	Buy	$178.00	High
5/6/2021	Citigroup	Upgrade	Neutral ➝ Buy	$160.00 ➝ $151.00	High
5/5/2021	Evercore ISI	Upgrade	In-Line ➝ Outperform	$144.00	High
5/5/2021	Morgan Stanley	Lower Target	Overweight	$170.00 ➝ $156.00	Low
4/19/2021	Morgan Stanley	Lower Target	Overweight	$175.00 ➝ $170.00	Medium
3/1/2021	Stifel Nicolaus	Initiated Coverage	Buy	$179.00	High
2/16/2021	SVB Leerink	Boost Target	Outperform	$115.00 ➝ $178.00	Low
2/12/2021	Wedbush	Boost Target	Neutral	$113.00 ➝ $130.00	Low
2/12/2021	Piper Sandler	Boost Target	Overweight	$165.00 ➝ $170.00	Low
2/12/2021	Barclays	Boost Target	Overweight	$176.00 ➝ $186.00	Low
2/12/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$165.00	Low
1/25/2021	Credit Suisse Group	Boost Target	Neutral	$64.00 ➝ $99.00	High
1/11/2021	Robert W. Baird	Boost Target	Outperform	$110.00 ➝ $165.00	Medium
1/11/2021	Barclays	Boost Target	Overweight	$121.00 ➝ $176.00	High
12/7/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$105.00 ➝ $110.00	Medium
11/24/2020	Evercore ISI	Reiterated Rating	In-Line	$110.00	High
11/12/2020	Bank of America	Downgrade	Buy ➝ Neutral	$104.00 ➝ $126.00	High
10/28/2020	Truist Financial	Boost Target		$88.00 ➝ $110.00	High
10/28/2020	Wedbush	Boost Target	Outperform	$97.00 ➝ $105.00	Low
10/28/2020	Morgan Stanley	Boost Target	Overweight	$89.00 ➝ $91.00	Low
10/28/2020	Barclays	Boost Target	Overweight	$99.00 ➝ $121.00	Medium
10/28/2020	SVB Leerink	Boost Target	Outperform	$110.00 ➝ $115.00	Medium
10/27/2020	Piper Sandler	Boost Target	Overweight	$83.00 ➝ $108.00	Medium
10/15/2020	Bank of America	Boost Target	Buy	$93.00 ➝ $107.00	Medium
10/13/2020	Morgan Stanley	Boost Target	Overweight	$87.00 ➝ $89.00	Medium
7/31/2020	Credit Suisse Group	Reiterated Rating	Hold	$64.00	Low
7/31/2020	Morgan Stanley	Lower Target	Overweight	$88.00 ➝ $87.00	High
7/31/2020	Barclays	Boost Target	Overweight	$87.00 ➝ $99.00	Low
7/28/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$84.00	High
7/15/2020	Morgan Stanley	Boost Target	Overweight	$83.00 ➝ $88.00	Low
7/1/2020	SunTrust Banks	Boost Target		$82.00 ➝ $88.00	Medium
7/1/2020	Credit Suisse Group	Boost Target	Neutral	$60.00 ➝ $64.00	High
7/1/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$76.00 ➝ $84.00	High
7/1/2020	Wedbush	Boost Target	Hold ➝ Outperform	$83.00 ➝ $91.00	High
7/1/2020	Morgan Stanley	Boost Target	Overweight	$79.00 ➝ $83.00	High
7/1/2020	Robert W. Baird	Boost Target	Outperform	$75.00 ➝ $90.00	High
6/30/2020	Piper Sandler	Boost Target	Overweight	$70.00 ➝ $83.00	High
6/19/2020	SunTrust Banks	Boost Target	Buy	$80.00 ➝ $82.00	High
6/19/2020	Wedbush	Boost Target	Outperform	$73.00 ➝ $83.00	High
5/18/2020	Stifel Nicolaus	Boost Target	Positive ➝ Buy	$70.00 ➝ $82.00	High
5/8/2020	Citigroup	Boost Target	Neutral	$53.00 ➝ $66.00	Low
4/1/2020	Robert W. Baird	Reiterated Rating	Buy	$75.00	High
2/18/2020	Evercore ISI	Reiterated Rating	Buy		Low
2/16/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$76.00	Low
2/14/2020	Wedbush	Boost Target	Outperform	$71.00 ➝ $75.00	High
2/14/2020	Cowen	Reiterated Rating	Buy	$75.00	High
1/17/2020	Morgan Stanley	Boost Target	Overweight	$73.00 ➝ $77.00	Low
1/10/2020	SunTrust Banks	Reiterated Rating	Buy	$75.00 ➝ $80.00	High
1/2/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		High
12/18/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$70.00	High
12/18/2019	Cowen	Reiterated Rating	Buy	$59.00	High
12/17/2019	Morgan Stanley	Lower Target	Overweight	$76.00 ➝ $73.00	Medium
11/6/2019	Morgan Stanley	Lower Target	Overweight	$79.00 ➝ $76.00	High
11/6/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	High
11/5/2019	Cowen	Reiterated Rating	Buy	$62.00	High
9/4/2019	Piper Jaffray Companies	Set Target	Buy	$75.00	Low
9/4/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
9/4/2019	SVB Leerink	Reiterated Rating	Outperform ➝ Positive	$80.00 ➝ $85.00	High
8/15/2019	Wedbush	Reiterated Rating	Buy	$75.00	High
8/15/2019	Cowen	Reiterated Rating	Buy		High
8/5/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Medium
8/4/2019	Barclays	Reiterated Rating	Buy	$87.00	Medium
8/2/2019	Morgan Stanley	Lower Target	Overweight	$83.00 ➝ $79.00	High
8/2/2019	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$75.00	High
6/17/2019	Morgan Stanley	Set Target	Buy	$83.00	Low
5/9/2019	Barclays	Reiterated Rating	Buy		Low
5/7/2019	Wedbush	Reiterated Rating	Outperform	$88.00 ➝ $77.00	High
3/27/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$68.00 ➝ $83.00	Medium
2/26/2019	Cowen	Reiterated Rating	Buy	$69.00	High
2/22/2019	Raymond James	Reiterated Rating	Outperform ➝ Outperform	$80.00	Low
2/21/2019	Citigroup	Boost Target	Neutral ➝ Neutral	$54.00 ➝ $62.00	High
2/20/2019	Credit Suisse Group	Reiterated Rating	Hold	$59.00	High
1/23/2019	SunTrust Banks	Boost Target	Buy	$71.00	High
1/7/2019	Wedbush	Reiterated Rating	Outperform	$88.00	Medium
1/7/2019	Cowen	Reiterated Rating	Buy		Medium
1/4/2019	Credit Suisse Group	Set Target	Hold	$59.00	Medium
1/2/2019	Raymond James	Downgrade	Outperform ➝ Market Perform		Medium
11/15/2018	Credit Suisse Group	Set Target	Hold	$59.00	High
11/14/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
11/8/2018	Citigroup	Upgrade	Sell ➝ Neutral	$46.00 ➝ $54.00	N/A
11/6/2018	Raymond James	Boost Target	Outperform ➝ Buy	$53.00 ➝ $57.00	Medium
10/29/2018	Wedbush	Lower Target	Outperform ➝ Outperform	$90.00 ➝ $88.00	High
10/29/2018	Citigroup	Lower Target	Sell ➝ Sell	$49.00 ➝ $46.00	High
10/29/2018	Morgan Stanley	Set Target	Hold	$92.00 ➝ $70.00	High
10/29/2018	Credit Suisse Group	Lower Target	Neutral ➝ Hold	$78.00 ➝ $59.00	High
10/29/2018	SunTrust Banks	Lower Target	Buy ➝ Buy	$83.00 ➝ $54.00	Medium
10/27/2018	JPMorgan Chase & Co.	Set Target	Buy	$68.00	Medium
10/26/2018	Raymond James	Set Target	Buy	$70.00	Low
10/26/2018	Piper Jaffray Companies	Lower Target	Overweight	$70.00	High
10/7/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy	$86.00	Low
9/11/2018	Bank of America	Boost Target	Buy ➝ Buy	$72.00 ➝ $94.00	Low
9/10/2018	Morgan Stanley	Reiterated Rating	Equal ➝ Equal Weight	$92.00	Low
9/2/2018	JMP Securities	Reiterated Rating	Buy	$94.00	Medium
8/30/2018	Wedbush	Boost Target	Outperform ➝ Outperform	$80.00 ➝ $90.00	Medium
8/29/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
8/20/2018	SunTrust Banks	Boost Target	Buy ➝ Positive	$83.00	Low
8/6/2018	Wedbush	Boost Target	Outperform ➝ Outperform	$71.00 ➝ $80.00	High
8/3/2018	Robert W. Baird	Reiterated Rating	Buy	$95.00	High
8/3/2018	Barclays	Reiterated Rating	Overweight ➝ Overweight	$74.00 ➝ $92.00	High
8/3/2018	Piper Jaffray Companies	Boost Target	Overweight	$85.00	High
7/17/2018	SVB Leerink	Boost Target	Outperform ➝ Outperform	$68.00 ➝ $95.00	Low
6/21/2018	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$67.00 ➝ $80.00	High
5/11/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$62.00 ➝ $74.00	High
5/10/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$63.00	Medium
4/18/2018	Cowen	Reiterated Rating	Buy		Medium
4/18/2018	Stifel Nicolaus	Boost Target	Buy ➝ Buy	$74.00 ➝ $77.00	High
4/18/2018	Wedbush	Reiterated Rating	Outperform ➝ Positive	$64.00 ➝ $71.00	High
4/18/2018	JMP Securities	Boost Target	Outperform	$70.00 ➝ $74.00	High
4/18/2018	SunTrust Banks	Upgrade	Hold ➝ Buy	$41.67 ➝ $55.00	Low
4/17/2018	Bank of America	Boost Target		$61.00 ➝ $72.00	Low
3/22/2018	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$67.00	Medium
2/23/2018	Robert W. Baird	Reiterated Rating	Buy	$70.00	Medium
2/21/2018	Bank of America	Boost Target	Buy ➝ Buy	$60.00 ➝ $61.00	High
2/21/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$57.00 ➝ $60.00	High
2/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Market Outperform ➝ Overweight	$68.00 ➝ $66.00	High
2/21/2018	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $74.00	High
1/22/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform		High
1/17/2018	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$67.00	Low
12/15/2017	Raymond James	Reiterated Rating	Buy		Low
12/5/2017	Raymond James	Reiterated Rating	Buy		Medium
12/5/2017	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $62.00	High
12/4/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$58.00 ➝ $72.00	High
11/15/2017	Cowen	Reiterated Rating	Buy		N/A
11/5/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$76.00	N/A
11/3/2017	Robert W. Baird	Lower Target	Outperform	$85.00 ➝ $80.00	N/A
10/6/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$69.00 ➝ $71.00	N/A

(Data available from 9/28/2017 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
5 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/2/2022

1 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/1/2022

4 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

5/1/2022

3 very positive mentions
9 positive mentions
4 negative mentions
2 very negative mentions

Mentions as of

5/31/2022

2 very positive mentions
3 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

6/30/2022

5 very positive mentions
10 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

7/30/2022

1 very positive mentions
3 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

8/29/2022

2 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/28/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

uk.finance.yahoo.com
9/24/2022
Ultragenyx Pharmaceutical Inc. (RARE)
marketbeat.com
9/12/2022
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Brokerages
nasdaq.com
9/6/2022
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) insiders sold US$2.9m worth of stock, possibly signalling a downtrend
marketbeat.com
9/5/2022
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts
seekingalpha.com
9/1/2022
Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue

Very Positive

finance.yahoo.com
9/9/2022
Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
finance.yahoo.com
9/1/2022
Ultragenyx to Participate at Citi BioPharma Conference

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $41.27

$40.56

$41.64

50 Day Range

MA: $48.79

$39.96

$55.77

52 Week Range

Now: $41.27

$39.75

$91.10

Volume

732,630 shs

Average Volume

564,463 shs

Market Capitalization

$2.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?: The following equities research analysts have issued reports on Ultragenyx Pharmaceutical in the last twelve months: Barclays PLC, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for RARE.
What is the current price target for Ultragenyx Pharmaceutical?: 12 Wall Street analysts have set twelve-month price targets for Ultragenyx Pharmaceutical in the last year. Their average twelve-month price target is $111.58, suggesting a possible upside of 170.4%. Stifel Nicolaus has the highest price target set, predicting RARE will reach $142.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $60.00 for Ultragenyx Pharmaceutical in the next year.
View the latest price targets for RARE.
What is the current consensus analyst rating for Ultragenyx Pharmaceutical?: Ultragenyx Pharmaceutical currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RARE will outperform the market and that investors should add to their positions of Ultragenyx Pharmaceutical.
View the latest ratings for RARE.
What other companies compete with Ultragenyx Pharmaceutical?: Other companies that are similar to Ultragenyx Pharmaceutical include Galapagos, Amicus Therapeutics, AbCellera Biologics, ACADIA Pharmaceuticals and Arrowhead Pharmaceuticals. Learn More about companies similar to Ultragenyx Pharmaceutical.
How do I contact Ultragenyx Pharmaceutical's investor relations team?: Ultragenyx Pharmaceutical's physical mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company's listed phone number is (415) 483-8800 and its investor relations email address is [email protected] The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. Learn More about contacing Ultragenyx Pharmaceutical investor relations.

Ultragenyx Pharmaceutical - RARE Stock Price Target and Predictions

Analyst Price Target for RARE

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.39 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?

What is the current price target for Ultragenyx Pharmaceutical?

What is the current consensus analyst rating for Ultragenyx Pharmaceutical?

What other companies compete with Ultragenyx Pharmaceutical?

How do I contact Ultragenyx Pharmaceutical's investor relations team?